This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parize, P.
Right arrow Articles by Lortholary, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parize, P.
Right arrow Articles by Lortholary, O.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2009, p. 1048-1053, Vol. 53, No. 3
0066-4804/09/$08.00+0     doi:10.1128/AAC.01220-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Antifungal Therapy of Aspergillus Invasive Otitis Externa: Efficacy of Voriconazole and Review{triangledown}

Perrine Parize,1 Marie-Olivia Chandesris,1 Fanny Lanternier,1 Sylvain Poirée,1 Jean-Paul Viard,1 Boris Bienvenu,2 Michaël Mimoun,3 Frédéric Méchai,1 Marie-France Mamzer,1 Philippe Herman,4 Marie-Elisabeth Bougnoux,1 Marc Lecuit,1,5 and Olivier Lortholary1,5*

Université Paris Descartes, Hôpital Necker-Enfants Malades, Paris, France,1 Hôpital Cochin—Saint-Vincent de Paul, Paris, France,2 Hôpital Européen Georges-Pompidou, Paris, France,3 Hôpital Lariboisière, Paris, France,4 Institut Pasteur, Paris, France5

Received 15 September 2008/ Returned for modification 11 October 2008/ Accepted 20 November 2008

Invasive otitis externa (IOE) due to Aspergillus is a rare, potentially life-threatening, invasive fungal infection affecting immunocompromised patients. The invasive process may lead to skull base osteomyelitis with progressive cranial nerve palsies and can result in irreversible hearing and neurological impairment. We report two cases of Aspergillus IOE treated with voriconazole alone and a literature review of antifungal therapy of Aspergillus IOE. Twenty-five patients, including the two described in the present report, were analyzed. Eighteen patients were treated with amphotericin B, and nine of them received itraconazole as an additional agent. Three patients received initial therapy with itraconazole, and one patient was treated with both voriconazole and caspofungin therapy. The two patients in the present report received voriconazole therapy alone with good clinical and biological tolerance despite prolonged treatment. The last patient did not receive antifungal therapy, as the diagnosis was made postmortem. Eighteen patients underwent an initial extensive surgical debridement. The majority of the patients had a favorable outcome, 17 patients experienced a complete recovery, and 6 showed a partial improvement. Both of the patients reported on here had favorable outcomes, and no aggressive surgical debridement was required. Although voriconazole has been shown to be effective for the treatment of invasive aspergillosis, its precise role in the management of Aspergillus IOE had not been documented. These observations demonstrate that voriconazole could be an effective and well-tolerated therapeutic option for the management of Aspergillus IOE.


* Corresponding author. Mailing address: Paris Descartes University, Department of Infectious Diseases and Tropical Medicine, Necker-Enfants Malades Hospital, Necker-Pasteur Infectiology Center, 149, rue de Sèvres, 75743 Paris Cedex 15, France. Phone: (33) 01 42 19 26 63. Fax: (33) 01 42 19 26 22. E-mail: olivier.lortholary{at}nck.aphp.fr

{triangledown} Published ahead of print on 22 December 2008.


Antimicrobial Agents and Chemotherapy, March 2009, p. 1048-1053, Vol. 53, No. 3
0066-4804/09/$08.00+0     doi:10.1128/AAC.01220-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.